20/20 Biolabs Inc
AIDX
15 hedge funds and large institutions have $297K invested in 20/20 Biolabs Inc in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
114% more funds holding
Funds holding: 7 → 15 (+8)
1.3% more ownership
Funds ownership: 3.11% → 4.41% (+1.3%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
47% less capital invested
Capital invested by funds: $565K → $297K (-$268K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$112K |
| 2 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$65.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.7K |
| 4 |
AUB
Atlantic Union Bankshares
Glen Allen,
Virginia
|
+$44.1K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$30.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
-$30.4K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$19.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$1.88K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$72 |
AIDX Hedge Fund Activity: Q2 2026 in Review
15 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in 20/20 Biolabs Inc (AIDX) for Q2 2026, worth a combined $297K — down 47% from $565K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new AIDX positions and 2 closed out — a net gain of 8 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $112K. The largest seller was Cresset Asset Management, cutting an estimated $30.4K.
- 15 institutional investors held 20/20 Biolabs Inc (AIDX) as of Q2 2026, up from 7 in Q1 2026.
- Funds reported $297K of 20/20 Biolabs Inc stock for Q2 2026, down 47% quarter-over-quarter.
- 10 funds opened new 20/20 Biolabs Inc positions in Q2 2026 and 2 closed out, a net change of +8 holders.
- The largest 20/20 Biolabs Inc buyer in Q2 2026 was HRT Financial, an estimated $112K added.
- The largest 20/20 Biolabs Inc seller in Q2 2026 was Cresset Asset Management, an estimated $30.4K sold.
Based on aggregated 13F filings for Q2 2026.